SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AutoImmune-AIMM
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Daniel Goncharoff who wrote (14)3/9/1997 8:20:00 PM
From: organ   of 298
 
I am a graduate student in neuroscience and recently attended a
conference on MS, the disease that Myloral is supposed to cure. One scientist who was giving a presentation indicated to me privately
that the oral tolerance technology seemed to work well enough in rats, but that Autoimmune's clinical phase III trials in humans were going
very badly and that they were showing statistically insignificant
results. The safety profile is fine but the efficacy is not there.
Remarkably, some individuals show complete remission but not enough
people show an improvement in the clinical symptoms. The stock is
going to go through the floor, no doubt. The cash flow problems will
only exacerbate the problem. I think that some of the insiders already know that there are problems, which is causing this wave of
selling that we are seeing now in the stock.

Can you please post this globally if this only goes to you locally? Thanks and good luck!

Mark Organ
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News